Preller KH

Department of Psychiatry, Yale University School of Medicine; New Haven, CT, USA; Department of Adult Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zurich, Switzerland.

49 papers · 9 preprints · ORCID

ArticleKetamine

Ketamine Alters Tuning of Neural and Behavioral Spatial Working Memory Precision.

Rahmati M, Moujaes F, Suljic NP +22

Europe PMC2026
ArticlePsilocybin

Effects of psychedelic drug use on neurocognitive function and the psychological and social domains of quality of life: an international online study.

Stadler F, Saelens J, Henter ID +6

Europe PMC2026
ArticlePsilocybin

Psychedelics align brain activity with context.

Stoliker D, Novelli L, Khajehnejad M +16

Europe PMC2026
ArticlePsilocybin

Blinding integrity in psychedelic research: Evidence from a comparative randomized controlled trial of psilocybin, MDMA, and methylphenidate in healthy volunteers.

Belinger L, Rieser NM, Engeli EJE +8

Europe PMC2026
ArticlePsilocybin

Epigenome-wide association study of psilocybin-induced methylome changes in alcohol use disorder.

Urban MM, Zillich L, Rieser NM +5

Europe PMC2026
ArticlePsilocybin

An international mega-analysis of psychedelic drug effects on brain circuit function.

Girn M, Doss MK, Roseman L +24

Europe PMC2026
ArticleMDMA

Memory deficits of MDMA users are linked to cortical thinning related to 5-HT receptor densities.

Coray RC, Beliveau V, Zimmermann J +8

Europe PMC2026
ArticlePsychedelics

Neurobiological Correlates of Psychedelic Experiences and Psychedelic-Associated Adverse Effects.

Rieser NM, Schmidt TT, Preller KH

Europe PMC2026
ArticlePsychedelics

Correction: Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology.

Shinozuka K, Jerotic K, Mediano P +4

Europe PMC2025
PreprintPsilocybin

Neurocomputational evidence of sustained Self-Other mergence after psychedelics

Mallaroni P, Mason NL, Preller KH +3

Europe PMC2025
ArticlePsilocybin

Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases.

Heller NH, Barrett FS, Buchborn T +10

Europe PMC2025
PreprintPsychedelics

Effects of Psychedelic Drug Use on Neurocognitive Function and Psychological and Social Quality of Life Domains: An International Online Study

Stadler F, Saelens J, Henter I +6

Europe PMC2025
ArticlePsilocybin

The emotional architecture of the psychedelic brain.

Moujaes F, Rieser NM, Belinger L +3

Europe PMC2025
PreprintPsilocybin

Epigenome-wide Association Study of Psilocybin-Induced Methylome Changes in Alcohol Use Disorder

Urban MM, Zillich L, Rieser NM +5

Europe PMC2025
PreprintPsilocybin

Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases

Heller NH, Barrett FS, Buchborn T +10

Europe PMC2025
ArticlePsilocybin

Neurocognitive effects of psilocybin: A systematic and comprehensive review of neuroimaging studies in humans.

Berkovitch L, Fauvel B, Preller KH +1

Europe PMC2025
ArticlePsychedelics

Pictorial representation of illness and self measure (PRISM): A putative transdiagnostic tool for evaluating therapeutic effects of psychedelic treatments.

Pouyan N, Aday JS, Harte SE +11

Europe PMC2025
ArticlePsychedelics

Correction: Neural mechanisms of psychedelic visual imagery.

Stoliker D, Preller KH, Novelli L +4

Europe PMC2025
PreprintPsilocybin

Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases

Heller NH, Barrett FS, Buchborn T +10

Europe PMC2025
ArticlePsilocybin

Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial.

Rieser NM, Bitar R, Halm S +14

Europe PMC2025
PreprintPsilocybin

Psychedelics Align Brain Activity with Context

Stoliker D, Novelli L, Khajehnejad M +16

Europe PMC2025
ArticlePsilocybin

A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research.

Yaden DB, Graziosi M, Owen AM +39

Europe PMC2025
PreprintPsilocybin

Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases

Heller NH, Barrett FS, Buchborn T +10

Europe PMC2025
ArticlePsilocybin

Psilocybin increases emotional empathy in patients with major depression.

Jungwirth J, von Rotz R, Dziobek I +2

Europe PMC2025
ArticlePsilocybin

Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology.

Shinozuka K, Jerotic K, Mediano P +4

Europe PMC2024
ArticlePsilocybin

Neural mechanisms of psychedelic visual imagery.

Stoliker D, Preller KH, Novelli L +4

Europe PMC2025
ArticlePsilocybin

The influence of psilocybin on subconscious and conscious emotional learning.

Casanova AF, Ort A, Smallridge JW +3

Europe PMC2024
ArticleKetamine

Ketamine induces multiple individually distinct whole-brain functional connectivity signatures.

Moujaes F, Ji JL, Rahmati M +23

Europe PMC2024
ArticlePsilocybin

Neural Mechanisms of Resting-State Networks and the Amygdala Underlying the Cognitive and Emotional Effects of Psilocybin.

Stoliker D, Novelli L, Vollenweider FX +3

Europe PMC2024
ArticlePsilocybin

Amygdala response to emotional faces following acute administration of psilocybin in healthy individuals.

Armand S, Larsen K, Larsen K +6

Europe PMC2024
ArticlePsilocybin

Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms.

McCulloch DE, Lopez JP, Dalla C +7

Europe PMC2024
ArticlePsilocybin

Psilocybin-induced changes in cerebral blood flow are associated with acute and baseline inter-individual differences.

Rieser NM, Gubser LP, Moujaes F +5

Europe PMC2023
PreprintPsilocybin

Synergistic, Multi-level Understanding of Psychedelics: Three Systematic Reviews and Meta-analyses of Their Pharmacology, Neuroimaging and Phenomenology

Shinozuka K, Jerotic K, Mediano P +4

Europe PMC2023
ArticleMDMA

Effective Connectivity of Thalamocortical Interactions Following d-Amphetamine, LSD, and MDMA Administration.

Avram M, Müller F, Preller KH +8

Europe PMC2024
ArticlePsilocybin

Comparing Neural Correlates of Consciousness: From Psychedelics to Hypnosis and Meditation.

Moujaes F, Rieser NM, Phillips C +9

Europe PMC2024
ArticlePsilocybin

TMS-EEG and resting-state EEG applied to altered states of consciousness: oscillations, complexity, and phenomenology.

Ort A, Smallridge JW, Sarasso S +7

Europe PMC2023
ArticlePsilocybin

Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial.

von Rotz R, Schindowski EM, Jungwirth J +9

Europe PMC2023
ArticlePsychedelics

The neural basis of psychedelic action.

Kwan AC, Olson DE, Preller KH +1

Europe PMC2022
PreprintPsilocybin

Neural mechanisms of psychedelic visual imagery

Stoliker D, Preller KH, Novelli L +4

Europe PMC2022
ArticleLSD

Effective Connectivity of Functionally Anticorrelated Networks Under Lysergic Acid Diethylamide.

Stoliker D, Novelli L, Vollenweider FX +3

Europe PMC2023
ArticlePsilocybin

Editorial: Psychedelic sociality: Pharmacological and extrapharmacological perspectives.

Roseman L, Preller KH, Fotiou E +1

Europe PMC2022
ArticlePsilocybin

Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses.

McCulloch DE, Knudsen GM, Barrett FS +10

Europe PMC2022
ArticlePsychedelics

A neurobiological perspective on social influence: Serotonin and social adaptation.

Duerler P, Vollenweider FX, Preller KH

Europe PMC2022
ArticlePsilocybin

Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action.

Rieser NM, Herdener M, Preller KH

Europe PMC2022
ArticleLSD

Transcriptomics-informed large-scale cortical model captures topography of pharmacological neuroimaging effects of LSD.

Burt JB, Preller KH, Demirtas M +5

Europe PMC2021
ArticleLSD

LSD and ketanserin and their impact on the human autonomic nervous system.

Olbrich S, Preller KH, Vollenweider FX

Europe PMC2021
ArticlePsilocybin

Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders.

Mertens LJ, Preller KH

Europe PMC2021
ArticlePsychedelics

Hallucinations Under Psychedelics and in the Schizophrenia Spectrum: An Interdisciplinary and Multiscale Comparison.

Leptourgos P, Fortier-Davy M, Carhart-Harris R +11

Europe PMC2020
ArticlePsilocybin

Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.

De Gregorio D, Aguilar-Valles A, Preller KH +4

Europe PMC2021
ArticlePsilocybin

Rostral Anterior Cingulate Thickness Predicts the Emotional Psilocybin Experience.

Lewis CR, Preller KH, Braden BB +2

Europe PMC2020
ArticleLSD

Preliminary Report on the Effects of a Low Dose of LSD on Resting-State Amygdala Functional Connectivity.

Bershad AK, Preller KH, Lee R +4

Europe PMC2020
ArticlePsychedelics

Modulation of Social Cognition <i>via</i> Hallucinogens and "Entactogens".

Preller KH, Vollenweider FX

Europe PMC2019
ArticleLSD

Effective connectivity changes in LSD-induced altered states of consciousness in humans.

Preller KH, Razi A, Zeidman P +3

Europe PMC2019
ArticleLSD

Serotonin 2A Receptor Signaling Underlies LSD-induced Alteration of the Neural Response to Dynamic Changes in Music.

Barrett FS, Preller KH, Herdener M +2

Europe PMC2018
ArticlePsilocybin

Psychedelics and music: neuroscience and therapeutic implications.

Barrett FS, Preller KH, Kaelen M

Europe PMC2018
ArticlePsilocybin

Phenomenology, Structure, and Dynamic of Psychedelic States.

Preller KH, Vollenweider FX

Europe PMC2018
ArticleLSD

LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation.

Kraehenmann R, Pokorny D, Aicher H +5

Europe PMC2017
ArticlePsilocybin

Effect of Psilocybin on Empathy and Moral Decision-Making.

Pokorny T, Preller KH, Kometer M +2

Europe PMC2017